TriangleBiospecimen Collection (NCT06959641)
Biospecimen Collection trial for Locally Advanced Differentiated Thyroid Gland Carcinoma (NCT06959641). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with locally advanced or metastatic differentiated thyroid cancer that is radioiodine-refractory and progressed within twelve months. Prior systemic anticancer therapy other than radioiodine is excluded.
The idea: XL092, or zanzalintinib, blocks growth and blood-vessel signaling through several kinases. Patients take it daily in twenty-one-day cycles until progression or unacceptable toxicity. Scans, blood tests, urine tests, and questionnaires track cancer control, safety, and quality of life. Researchers assess twelve-month progression-free survival.
This phase 2 study plans 33 patients. Jochen Lorch leads at Northwestern, Chicago; two US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.